Going-concern and financing risk
The company states it may need additional capital to continue operations and fund growth.
- Scope
- Operating continuity and commercialization funding
- Materiality
- high
Positron Corp
Positron Corp is a U.S.-based medical technology company focused on PET and PET-CT imaging systems for nuclear medicine. The company develops, manufactures, and sells imaging equipment and supports customers with maintenance services, clinical support, and related commercial arrangements from its headquarters in North Tonawanda, New York.
−2 269,2 %
−458,2 %
−2 297,8 %
−21,5 %
1.39
1.11
| % | |
|---|---|
| PET and PET-CT imaging systems | 70% Capital equipment used for molecular imaging in cardiac, oncology, and neurology applications. |
| Maintenance service contracts | 30% Recurring service agreements that provide ongoing support and system uptime for installed equipment. |
Positron sells to healthcare providers that use molecular imaging for diagnosis and treatment planning, especially in...
- Hospitals and health systemsprimary
Buy PET and PET-CT systems for inpatient and outpatient diagnostic imaging and long-term service support.
- Outpatient imaging centersprimary
Purchase systems and maintenance contracts to offer molecular imaging without building in-house technology.
- Physician practicessecondary
Use Positron systems for specialized nuclear cardiology workflows and recurring service coverage.
- OEM and distribution partnerssecondary
Support broader commercialization and market reach for PET and PET-CT products.
Positron is headquartered in North Tonawanda, New York and is organized as a U.S. company...
- •Headquartered in North Tonawanda, New York
- •U.S. incorporation and primary operating base
- •North American market focus for PET and PET-CT commercialization
- •Distribution rights tied to the North American market
- •Healthcare demand is driven by U.S. nuclear medicine adoption
Positron’s strategy centers on expanding its PET-CT offering, broadening use in nuclear cardiology, and supporting...
01
Commercialize PET-CT systems in North Americashort-term
Broader adoption is central to scaling the installed base and creating recurring service revenue.
02
Expand clinical use cases beyond cardiac PETmedium-term
Oncology and neurology can enlarge the addressable market and reduce dependence on one specialty.
03
Strengthen service and uptime supportmedium-term
Maintenance contracts improve customer retention and support the value proposition of installed equipment.
Positron faces execution risk in commercializing its imaging systems, including customer adoption, competitive...
Customer adoption and market acceptance risk
PET and PET-CT systems require clinical acceptance and buyer confidence before scaling.
- Scope
- Equipment sales and installed-base growth
- Materiality
- high
Competitive risk
The imaging market includes established competitors with broader product portfolios and sales reach.
- Scope
- Pricing, win rates, and distribution access
- Materiality
- medium
Revenue timing risk on equipment sales
Revenue is recognized only when control transfers, so delayed delivery or acceptance postpones revenue.
- Scope
- Quarterly revenue volatility
- Materiality
- medium
Revenue recognition timing
Reported revenue depends on service periods and equipment delivery/acceptance
Deferred revenue and contract liabilities
Affects balance sheet liabilities and future revenue visibility
Financial instruments with liability/equity characteristics
Can affect classification, dilution analysis, and equity balances
: 16.6.2026